Stem Cells International is a premier open access journal published by HINDAWI LTD, focusing on the rapidly evolving field of stem cell research. With an ISSN of 1687-966X and E-ISSN 1687-9678, this journal has been a vital resource since its inception in 2010, showcasing innovative studies and breakthroughs up to 2024. Positioned in Q3 in Cell Biology and Q2 in Molecular Biology for 2023, as well as well-ranked in the Scopus database, the journal serves as an essential platform for researchers, professionals, and students dedicated to exploring the implications of stem cell technology in regenerative medicine and biological research. The open access model ensures wide accessibility, fostering collaboration and knowledge-sharing across the scientific community, making it a cornerstone in advancing the understanding and application of stem cell science.

Regenerative Medicine, published by Taylor & Francis Ltd, is a pivotal journal within the field of biomedical research, focusing on the innovative advances in regenerative and restored functions in human health. With an ISSN of 1746-0751 and an E-ISSN of 1746-076X, this esteemed journal boasts a commendable impact factor within its categories, notably holding the Q2 status in Embryology and Q3 in Biomedical Engineering as of 2023. Covering a broad spectrum of topics from stem cell research to tissue engineering, it serves as a crucial platform for interdisciplinary collaboration among researchers, professionals, and students dedicated to the regeneration of tissues and organs. Given its comprehensive scope from 2006 to 2024, the journal continues to attract high-quality manuscripts that advance the frontiers of knowledge in regenerative medicine. Researchers and practitioners alike are encouraged to engage with the latest findings and methodologies disseminated in this vital publication.

Regenerative Engineering and Translational Medicine is an esteemed academic journal published by Springer Heidelberg, focusing on the interdisciplinary fields of biomaterials, biomedical engineering, and cell biology. With an ISSN of 2364-4133 and an E-ISSN of 2364-4141, the journal has carved a niche for itself since its inception in 2015, showcasing cutting-edge research that bridges the gap between scientific findings and practical applications in regenerative medicine. As a recognized platform in its field, it is currently positioned within Q3 quartiles in biomaterials, biomedical engineering, and medicine (miscellaneous), with a Scopus ranking that reflects its growing influence among peers. The journal aims to disseminate high-quality, peer-reviewed articles that highlight advancements in regenerative engineering, further advancing both theoretical and applied research. Scholars and practitioners seeking to stay at the forefront of the ever-evolving landscape of regenerative health solutions will find invaluable insights and innovations within these pages. Join a community of leading thinkers and explore the journal's comprehensive research contributions, which are crucial for fostering partnerships between academia and industry in the quest for transformative medical solutions.

Cells, published by MDPI in Switzerland, is a leading open-access journal that has been disseminating groundbreaking research in the fields of Biochemistry, Genetics, and Molecular Biology since its inception in 2011. With an impressive E-ISSN of 2073-4409, the journal boasts a strong impact factor and ranks in the 84th percentile for Scopus ratings, underscoring its significance in advancing scientific knowledge. As a Q1-ranked journal in both 2023 and 2020, it serves as a premier platform for researchers, professionals, and students eager to explore innovative findings and methodologies. By providing unrestricted access to high-quality research, Cells plays a pivotal role in facilitating collaboration and inspiration within the global scientific community, making it an indispensable resource for anyone interested in cutting-edge discoveries in cellular biology.

Current Stem Cell Research & Therapy, published by Bentham Science Publishers Ltd, is a leading journal dedicated to advancing the field of stem cell research. With an ISSN of 1574-888X and an E-ISSN of 2212-3946, this journal has been a valuable resource since its inception in 2006 and continues to broaden its scope through 2024. Recognized in the Q2 quartile for Medicine (miscellaneous) and ranked in the 66th percentile among its peers, the journal plays a crucial role in disseminating high-quality, peer-reviewed research that explores both the therapeutic and biological implications of stem cells. Located in the United Arab Emirates, Current Stem Cell Research & Therapy embraces a global audience of researchers, professionals, and students, providing a vibrant platform for discourse and innovation. While the journal offers subscription-based access, it remains committed to enhancing the scientific community's understanding of stem cell therapy and its applications across various medical fields.

Regenerative Therapy is a premier open-access journal dedicated to advancing the fields of biomaterials, biomedical engineering, and developmental biology. Published by Elsevier in Japan, this journal has been an influential platform since its inception in 2015, contributing significantly to the global discourse on regenerative medicine. With an impressive Q2 ranking in major categories such as Biomaterials and Biomedical Engineering, it is recognized for its quality of research and innovation. Researchers seeking to disseminate their findings or explore cutting-edge developments will find Regenerative Therapy to be invaluable, reflecting current trends and fostering collaborations across interdisciplinary boundaries. The journal offers open access, ensuring that high-quality research is available to a broad audience and enhances the impact of scholarly work in the regenerative medicine community.

STEM CELLS AND DEVELOPMENT, published by Mary Ann Liebert, Inc., is a leading peer-reviewed journal dedicated to the rapidly advancing fields of stem cell biology and developmental science. With an ISSN of 1547-3287 and an E-ISSN of 1557-8534, the journal encompasses a broad range of topics central to understanding stem cells' roles in development and regeneration processes. It holds a prestigious standing within its category quartiles, ranking Q3 in Cell Biology, Q2 in Developmental Biology, and Q2 in Hematology for 2023. With its convergence from 2004 to 2024, STEM CELLS AND DEVELOPMENT fosters an innovative platform for researchers, professionals, and students to disseminate groundbreaking research, share insights, and explore novel therapeutic approaches. Open access options enhance the journal's visibility and accessibility, promoting a collaborative exchange of information among the scientific community. Positioned at the forefront of stem cell research and its applications, this journal is vital for anyone seeking to stay informed about the latest advancements and trends within these critical areas of study.

Stem Cells Translational Medicine, published by Oxford University Press, is a leading open-access journal that has been at the forefront of stem cell research since its launch in 2012. With an impressive impact across various categories, it occupies Q2 in Cell Biology and is highly recognized in Q1 for both Developmental Biology and Miscellaneous Medicine in 2023. Its strong Scopus rankings highlight its significance in the fields of Biochemistry, Genetics, and Molecular Biology, achieving an outstanding percentile ranking of 93rd in Developmental Biology. The journal provides a pivotal platform for researchers, professionals, and students to publish and access cutting-edge findings that contribute to the understanding and application of stem cell technology. With a commitment to disseminating high-quality scientific knowledge, Stem Cells Translational Medicine plays a vital role in advancing research and innovation within the rapidly evolving landscape of regenerative medicine.

CELL AND TISSUE BANKING, published by Springer, is a prominent journal dedicated to advancing the fields of biomaterials, biomedical engineering, cell biology, and transplantation. With its ISSN 1389-9333 and E-ISSN 1573-6814, the journal plays a crucial role in disseminating high-quality research from its inception in 2000 to its ongoing contributions through 2024. Situated in the Netherlands, it boasts a respectable 2023 impact factor with notable quartile rankings, positioning it within the Q3 category for biomaterials, biomedical engineering, and transplantation, and Q4 for cell biology. Furthermore, its Scopus rankings underscore its relevance and influence, particularly in the fields of medicine and engineering. Although it does not currently offer open access options, the journal remains a vital resource for researchers, professionals, and students alike, fostering innovation and knowledge transfer in the critical areas of cell and tissue sustainability.

Tissue Engineering and Regenerative Medicine, published by the Korean Tissue Engineering Regenerative Medicine Society, is a distinguished journal focusing on the interdisciplinary fields of tissue engineering, regenerative medicine, and related biomedical innovations. With an ISSN of 1738-2696 and an E-ISSN of 2212-5469, this journal disseminates cutting-edge research and advancements pivotal to developing therapeutic strategies that improve tissue function and repair. As a testament to its scholarly impact, it holds a Q2 ranking in both Biomedical Engineering and Medicine (miscellaneous) categories, reflecting its influence and relevance within the scientific community, particularly with a Scopus rank placing it in the 82nd percentile among similar journals. Although the journal does not offer open access, it provides vital insights and knowledge to researchers, professionals, and students involved in the quest for innovative solutions in medical science and engineering. With its convergence years extending from 2008 to 2024, the journal continues to be an essential platform for the dissemination of high-quality research that drives the field forward.